New 52 Week High Today

Vertex Pharmaceuticals Inc VRTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 05/24/24 EDT

455.08

-1.87 (-0.41%)

Volume

58,380

456.95

+6.15 (+1.36%)

Volume

991,842

52 week range

320.01 - 457.66

Open451.90
Day High457.66
Day Low449.42
Prev Close450.80
52 Week High457.66
52 Week High Date05/24/24
52 Week Low320.01
52 Week Low Date06/01/23

Key Stats

Market Cap117.918B
Shares Out258.05M
10 Day Average Volume1.11M
Dividend-
Dividend Yield-
Beta0.41
YTD % Change12.3

KEY STATS

Open451.90
Day High457.66
Day Low449.42
Prev Close450.80
52 Week High457.66
52 Week High Date05/24/24
52 Week Low320.01
52 Week Low Date06/01/23
Market Cap117.918B
Shares Out258.05M
10 Day Average Volume1.11M
Dividend-
Dividend Yield-
Beta0.41
YTD % Change12.3

RATIOS/PROFITABILITY

EPS (TTM)15.42
P/E (TTM)29.64
Fwd P/E (NTM)27.82
EBITDA (TTM)4.388B
ROE (TTM)24.38%
Revenue (TTM)10.185B
Gross Margin (TTM)86.86%
Net Margin (TTM)39.46%
Debt To Equity (MRQ)1.95%

EVENTS

Earnings Date07/30/2024(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest On Vertex Pharmaceuticals Inc

Final Trades: Pfizer, Vertex, Freeport-McMoran and QualcommMay 14, 2024CNBC.com
Stocks making the biggest moves after hours: Palantir, Lucid and moreMay 6, 2024CNBC.com
Interest rates and the AI rally stay top of mind for stock investors next weekMay 3, 2024CNBC.com

Content From Our Affiliates

Vertex Pharmaceuticals sees Q1 capex $20M-$205MMay 9, 2024TipRanks
Vertex’s High-Stakes Acquisition: Navigating the Uncertainties of the Alpine DealMay 9, 2024TipRanks
Stifel Nicolaus Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)May 8, 2024TipRanks
Biotech Alert: Searches spiking for these stocks todayMay 8, 2024TipRanks
Vertex Pharmaceuticals Sell Rating Maintained Amid Unsustainable Performance and Uncertain Pipeline ProgressMay 8, 2024TipRanks

Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage...

Jeffrey Leiden M.D., Ph.D

Executive Chairman of the Board

Reshma Kewalramani

President, Chief Executive Officer, Director

Stuart Arbuckle

Chief Operating Officer, Executive Vice President

Charles Wagner Jr.

Chief Financial Officer, Executive Vice President

Carmen Bozic M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

Address

50 Northern Avenue

Boston, MA

02210

United States

https://www.vrtx.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
ZTS Zoetis Inc	170.07	-0.83	-0.49%
GILD Gilead Sciences Inc	65.68	-0.49	-0.74%
HLN Haleon PLC	8.38	-0.08	-0.95%
TAK Takeda Pharmaceutical Co Ltd	13.12	+0.10	+0.77%
GSK GSK plc	45.12	-0.03	-0.07%